Zynquista FDA Approval Status
Last updated by Judith Stewart, BPharm on July 23, 2024.
FDA Approved: No
Brand name: Zynquista
Generic name: sotagliflozin
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 1
Zynquista (sotagliflozin) is a dual sodium-glucose co-transporter-1 and -2 inhibitor in development as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD).
- Sotagliflozin works by inhibiting sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2), two proteins responsible for glucose regulation. SGLT1 is responsible for glucose absorption in the gastrointestinal tract and SGLT2 is responsible for glucose reabsorption by the kidney.
- Sotagliflozin was first approved by the U.S. Food and Drug Administration (FDA) in 2023 under the brand name Inpefa for use in the treatment of heart failure. Inpefa is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
Development timeline for Zynquista
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
